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Selenocyanates and diselenides are potential antitumor agents. Here we report two 
series of selenium derivatives related to selenocyanates and diselenides containing 
carboxylic, amide and imide moieties. These compounds were screened for their 
potency and selectivity against seven tumor cell lines and two non-malignant cell lines. 
Results showed that MCF-7 cells were especially sensitive to the treatment, with seven 
compounds presenting GI50 values below 10 µM. Notably, the carboxylic selenocyanate 
8b and the cyclic imide 10a also displayed high selectivity for tumor cells. Treatment of 
MCF-7 cells with these compounds resulted in cell cycle arrest at S phase, increased 
levels of pJNK and pAMPK and caspase independent cell death. Autophagy inhibitors 
wortmannin and chloroquine partially prevented 8b and 10a induced cell death. 
Consistent with autophagy, increased Beclin1 and LC3-IIB and reduced SQSTM1/p62 
levels were detected. Our results point to 8b and 10a as autophagic cell death inducers. 

















Despite recent advances in development of anticancer ag nts, this illness remains a 
leading cause of disease-related death worldwide [1]. Due to their effect on several 
survival or death signaling pathways that may decide the fate of cancer cells [2, 3], 
therapies based on autophagy targeted agents are now in the focus of a wide range of 
researchers. Among the signaling pathways implicated in these processes, JNK 
activation has been proven to participate in multiple autophagic events such as Beclin1 
expression and autophagic-mediated cell death [4, 5].  Energetic stress has also been 
described to be a trigger for autophagy [6]; in this context, AMPK has been proven to 
have an essential role promoting autophagy by inhibting the mTORs regulatory cascade 
[7]. The phosphorylation of AMPK and JNK in autophagy-mediated cell death has been 
previously described in breast adenocarcinoma  [8, 9] and several other cancer types 
such as myeloma [10] and leukemia [11].  
During the past decade, extensive studies of selenium compounds have demonstrated 
their antitumor and chemopreventive activities in a vast array of experimental models 
[12]. These derivatives interfere with the redox home stasis and signaling of cancer 
cells. The mechanism by which they cause their effect include alterations in cell cycle 
checkpoints, proliferation, senescence, and death pways [13]. In addition, some 
selenium derivatives such as selenite, selenocysteine and Se-allylselenocysteine play an 
effective role in cancer treatment as autophagy inducers and modulators of the JNK 
signaling pathway [14-17]. 
Many chemical entities containing selenium, with potent antitumor activity, have been 
explored by the scientific community. Among them, selenocyanate [18] and diselenide 
[19] moieties have been highlighted due to their interesting antitumor properties. In this 















aminophenyl)diselenide (0a) and the corresponding selenocyanate (0b), were recently 
identified in our laboratory [20]. In order to obtain a second generation of selenium 
structures with improved activity, selectivity and water solubility these compounds have 
been used as a starting point to continue with their modulation [21]. It is remarkable that 
one of the limitations of the selenium derivatives is their poor water solubility which is 
detrimental for their bioavailability and drug development. To obtain compounds with 
improved pharmacokinetic properties, modifications i  the hydrophobic scaffold that 
improve water solubility are usually assayed. As an example of this strategy, 
introduction of a hydroxyl group in the phenyl ring of the natural product camptothecin 
has been shown to counteract efficiently this drawback [22]. Thus, a useful option when 
using this approach is to incorporate polar functional groups, such as acidic or basic 
groups. These fragments enable the possibility of salt formation and therefore might 
enhance water solubility [23, 24]. In this study, sub tantial efforts had been directed 
towards finding different chemical scaffolds that, while maintaining the cytotoxic 
activity, should increase the hydrophilicity further contributing to the solubility 
optimization. Among the structural features incorporated, we surmised that the 
introduction of the carboxylic core could be a logical approach for improving its 
aqueous solubility. This moiety is present in widely described organoselenium 
compounds such as 3,3’-diselenodipropionic acid [25]. In addition, the dicarboxylic 
acids are of special importance because of their versatility in the preparation of the 
corresponding cyclic imide homologs which are widely described in the literature as 
potential antitumor agents [26, 27].  
Taking into consideration the facts stated above and our previous work in the field of 
new selenium compounds as antitumor agents [21, 28-33], the present study aimed to 















moieties. The general outline of this series of comp unds is presented in Figure 1. 
Variations were made in the group linked to the carboxy feature through selection of 
different cyclic symmetric anhydrides commercially available such as maleic, succinic, 
phthalic... Finally, with the objective of widening the structural variations, a new 
anhydride was synthesized through the Diels-Alder cycloaddition. The rationality 
behind this proposal is the synthesis of a structural analog of norcantharidin, a well-
known active antitumor autophagy inducer [34].  
 
Figure 1. Structures of novel selenium containing compounds. 
2. Results and discussion 
2.1. Chemistry 
The seventeen compounds synthesized and presented in his work can be categorized 
into two different subseries according to their selenium moiety: 
- Diselenide derivatives containing carboxylic and amide or imide moieties (1a-3a, 
5a, 7a-11a).  
















The resulting compounds were numbered according to the corresponding anhydride 
used as starting material.  
 
Figure 2. General procedure of synthesis. 
Derivatives were synthesized following the synthetic path depicted in Figure 2. The 
corresponding anhydrides were reacted with either bis(4-aminophenyl)diselenide (0a) 
or 4-aminophenylselenocyanate (0b) in acetone at room temperature for 8 h up to 24 h. 
The formed precipitate was filtered and washed withn-hexane or ethyl ether to yield the 
final compounds. The mechanism proposed for this reaction is a nucleophilic acyl 
substitution illustrated in Figure 3A. Moreover, all our attempts to generate derivatives 
4a and 6a were unsuccessful since the reaction of the corresponding anhydrides with 0a 
in different conditions (temperature, solvents and catalyst) failed to yield the desired 
compound. Unfortunately, the alternative strategy of reducing their selenocyanate 
analogs (4b and 6b) to obtain derivatives 4a and 6a under different conditions only 
resulted in the degradation of the start-up derivatives. To obtain the cyclic imides (9a-















anhydride and sodium acetate. This reaction probably starts by a deprotonation of the 
carboxylic group, followed by the nucleophilic attack of the oxygen to the carbonyl 
group on the acetic anhydride followed by a subsequent intramolecular cyclization to 
yield the final cyclic imides. The reaction was quenched with water causing the prompt 
precipitation of the desired compound. The proposed m chanism of reaction to yield the 
cyclic imides is exemplified in Figure 3B.  
 
Figure 3. Mechanism proposed for the synthesis diselenide derivatives. Mechanism 
proposed for the synthesis of compounds 1a-3a, 5a and 7a-8a (A). Mechanism 
proposed for the synthesis of cyclic imide derivaties 9a-11a (B). 
 
2.2. Biology  
2.2.1. Cytotoxicity and antiproliferative activity  
The cytotoxic potential of the seventeen synthesized compounds was evaluated against 















derived from non-malignant tissue. Evaluation was performed at 48 h treatment 
following the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
methodology as previously described [33]. The cancer cell lines included in the panel 
were PC-3 (prostatic adenocarcinoma); HTB-54 (lung carcinoma), and HT-29 (colon 
carcinoma); MOLT-4 and CCRF-CEM (acute lymphoblastic leukemia); K-562 (chronic 
myelogenous leukemia) and MCF-7 (breast adenocarcinoma). The selected cell lines 
derived from non-malignant tissue were 184B5 and BEAS-2B. Cisplatin was used as 
positive control. In addition, the parent compounds bis(4-aminophenyl)diselenide (0a) 
and 4-aminophenylselenocyanate (0b) were tested as a reference to identify whether the 
second generation compounds accomplished the objective of improving potency and 
selectivity.  
To narrow down the number of derivatives moving on t  the full dose-response 
cytotoxic profiling assay, a two-dose concentration (100 µM and 10 µM) screening was 
first performed. The results obtained for the 10 µM treatment are shown in Figure 4. As 
shown in the figure, MCF-7 cells were the most sensitive cells toward the tested 
derivatives. In fact, seven compounds (1b, 2b, 4b, 8a, 8b, 9a and 10a) reduced cell 
growth to less than 50% when assayed at 10 µM in these cells. Some compounds also 
matched this threshold in PC-3, CCRF-CEM, HTB-54, MOLT-4 and HT-29 cells. 
However, none of the derivatives was able to reduce the cell growth effectively in K-
562, the most resistant cell line to the treatments. I erestingly, compounds 1b, 2b, 4b, 
8a, 8b, 9a and 10a did not significantly affect cell growth in 184B5 cells, thus 
suggesting a potential selectivity of the compounds for breast cancer cells. 
Consequently, those seven compounds were further analysed in full dose-response 















are shown in Table 1. Selectivity for tumor cells was estimated according to the 
formulas GI50 (184B5)/GI50 (MCF-7) and GI50 (BEAS-2B)/GI50(HTB-54) (Table 2).  
 
  































































































































































































































































Figure 4. Heat map representing average percentages of cell growth for every 















Table 1. Average values of GI50, TGI and LD50 (µM) for 48 h treatment. 
Code 
PC-3 HTB-54 HT-29 MOLT-4 CCRF-CEM K-562 MCF-7 
GI50


































































































































































0b 1.02 1.54 2.30 0.87 1.00 1.13 0.27 1.11 5.28 3.33 3.39 3.42 1.71 2.74 4.43 1.03 1.29 1.58 1.00 1.48 2.20 
0a 0.80 1.62 2.98 0.21 0.80 2.16 
<0.0
1 
1.78 8.37 3.84 5.95 8.06 5.28 16.87 42.82 0.95 1.19 1.48 0.75 0.96 1.16 
Cisplatin
* 
5.01 50.1 >100 n.d.# n.d.# n.d.# 7.94 >100 >100 1.58 
63.1
0 
>100 1.00 79.43 >100 5.01 >100 >100 3.16 >100 >100 
a GI50, concentration that reduces growth by 50% compared to control. 
b TGI, concentration that completely inhibits cell growth. c LC50, 

















Table 2. Average values of GI50, TGI and LD50 (µM) for 48 h treatment and 
calculated SI. 
 
a Selectivity index (SI) calculated as GI50 (184B5)/GI50 (MCF-7). 
b SI calculated as GI50 
(BEAS-2B)/GI50(HTB-54). 
 
As shown in Tables 1 and 2, derivatives 8a, 9a and 10a exhibited GI50 values under 10 
µM in three of the tested cancer cell lines. Besides, compounds 1b, 2b, 4b, 8b and 10a 
were highly selective for tumor cells in the breast model. Remarkably, though highly 
cytotoxic, parent compounds 0a and 0b showed low selectivity for breast cancer cells 
(SI < 9). Therefore, we decided to focus on the effcts of these compounds in the breast 
cancer cell line. When ranked in terms of potency and selectivity for breast cancer cells, 







 TGI  GI50 GI50 TGI LD50 
1b >100 >100 >100 >51.73 10.45 42.82 80.15 0.22 
2b >100 >100 >100 >12.98 4.43 24.63 >100 <0.39 
4b >100 >100 >100 15.46 52.93 >100 >100 <0.16 
8a 8.93 11.25 15.67 1.19 1.05 4.43 15.53 0.04 
8b 77.25 91.19 >100 23.19 15.82 51.02 77.25 0.33 
9a 40.51 63.07 86.29 6.74 1.97 43.62 73.77 0.24 
10a 60.78 >100 > 100 6.3×104 0.75 20.86 61.91 0.15 
0a 6.29 14.03 30.44 8.39 0.73 0.88 1.09 3.44 















SI, as the leader structure. Despite less cytotoxic, 1b and 8b were also highly selective. 
Among them, the analog derivative of norcantharidin (8b) was selected in order to 
evaluate whether this structure was able to mimic norcantharidin’s effect and induce 
autophagy. As a result, derivatives 8b and 10a were selected to further analyse their 
mechanism of action in MCF-7 cells. As only the highest concentration tested led to 
negative growth values as exemplified on Figure 5, these results uncover a mainly 
cytostatic profile.  
   
Figure 5. Dose response curves obtained for 8b (A) and 10a (B) in MCF-7 and 
MDA-MB-231 cell lines.  
 
Besides, comparison between 10a and 0a clearly showed a great enhancement in 
selectivity for the second generation compound. In fact, SI was 7,000 times higher for 
compound 10a than for 0a, its parent compound. This effect was less notorious when 
compound 8b was compared with 0b. However, both 10a and 8b succeeded in 
increasing the selectivity towards the cancer cells, thus meeting one of our goals.  
The importance of estrogen receptors (ER) in cell cyc e and cell proliferation in breast 
cancer cells, as well as the crucial role of estradiol synthesis pathways has been widely 
described. In fact, antiestrogens have been found to repress transcription of several ERα 
target genes in MCF-7 cells, specifically in S phase [35]. Besides, when MCF-7 cell 


















































cultures were exposed to a genotoxic agent higher levels of DNA damage in S- and 
G2/M-enriched cultures correlated with higher levels of CYP1A1 y CYP1B1 [36]. 
MCF-7 is an ERα expressing cell line. Therefore, to compare we decided to test 8b and 
10a in MDA-MB-231, a breast cancer cell line non-expressing ERα. Obtained results 
for MDA-MB-231 cells are shown in Figure 5. As shown in the figure, 8a and 10a 
dose-response curves in MDA-MB-231differ from those obtained in MCF-7 cells. 
Moreover, lying in the micromolar range GI50, TGI and LD50 values for 8b (GI50= 33.61 
µM, TGI= 61.92 µM and LD50= 83.92 µM) and 10a (GI50= 13.65 µM, TGI= 51.49 µM 
and LD50> 100 µM) are also higher than in MCF-7cells. These data suggest that ER 
signalling and/or estradiol metabolism play a relevant role in cytostatic effect displayed 
by 8b and 10a in MCF-7 cells.  
In terms of structure-activity relationship, most diselenide structures containing 
carboxylic moieties were discarded in the screening process. For instance, when 
comparing 8b with its diselenide homolog a complete loss of selectivity could be 
observed. On the other hand, if we stablish a comparison between carboxylic 
derivatives and their cyclic imide homologs data suggests that this modification was 
crucial for both potency and selectivity.  
2.2.2. Compounds 8b and 10a induce cell cycle arrest in S phase and cell death  
Many selenium containing compounds involve cell cycle regulation among their 
therapeutic effects [13]. Therefore, as a first approach to the mechanism of action we 
studied the effect of 8b and 10a on cell cycle. With this purpose, the cell cycle status of 
MCF-7 cell cultures treated with different concentrations of 8b and 10a and for 
different time points was determined by flow cytometry. Camptothecin was used as 
positive control. As shown in the Figure 6, both a reduction in the number of G0/ 1 















both compounds even at the lowest concentration (10 µM) and the shortest time tested 
(24 h). This result, indicative of S phase arrest was both dose (Figure 6A) and time 
(Figures 6B and C) dependent. 
 
  
Figure 6. Cell cycle phase distribution of MCF-7 cell cultures after treatment with 
compounds 8b and 10a. (A) Dose-dependent induction of cell cycle arrest after 48 h 
treatment with compounds 8b and 10a. Time-course analysis of cell cycle distribution at 
10 µM (B) and 40 µM (C) of 8b and 10a. Camptothecin (6 µM) was employed as a 
positive control. Results are expressed as a mean ± SEM of at least three independent 
experiments performed in duplicate. *p < 0.05, **p < 0.01 and ***p < 0.001 compared 
















To study the role of apoptosis in the induction of cell death by 8b and 10a, MCF-7 cells 
were incubated in the presence of increasing concentrations of 8b and 10a for 48 h. 
Then, the apoptotic status of the cells was studied by TUNEL. As shown in Figure 7A, 
when tested at concentrations higher than 40 µM, both compounds induced a significant 
increase in the number of death cells (subdiploid cells). Figure 7B shows that at 40 µM 
concentration the induction of cell death could be detected as soon as 24 h. 
   
Figure 7. Compounds 8b and 10a induced cell death in a dose- and time-dependent 
manner in MCF-7 cell cultures. Cells were treated with increasing concentrations of 
compounds 8b and 10a for 48 h (A) or at 40 µM concentration for different periods of 
time (B). Camptothecin was used as positive control. Results are expressed as a mean ± 
SEM of at least three independent experiments performed in duplicate. *p < 0.05 and 
**p < 0.01 compared to control cells. 
 
2.2.3. Compounds 8b and 10a induce autophagy-mediated cell death and AMPK/JNK 
pathway activation  
To further analyse the molecular mechanism by which 8b and 10a reduced MCF-7 cell 
viability, we explored the effect of pre-treatment of the cultures with either an 












































































VAD-FMK) on the induction of cell death by these compounds. As shown in Figure 8, 
pre-treatment of the cells with the PI3K inhibitor wortmannin or the lysosomal inhibitor 
chloroquine led to a significant reduction in the number of dead cells in the cultures 
after exposure to compounds 8b and 10a. However, pre-incubation of the cultures with 
Z-VAD-FMK could not prevent 8b and 10a-induced cell death. These results suggest 
that autophagy is the way by which 8b and 10a cause their effect.  
   
Figure 8. Cell death induced by compounds 8b and 10a is partially blocked by 
wortmannin or chloroquine but not by caspase inhibitor Z-VAD-FMK. Cell death 
determination in MCF-7 cell cultures pre-incubated with (A) 100 nM wortmannin, 10 
µM chloroquine or (B) 50 mM Z-VAD-FMK before treatment with 80 µM 8b, 80 µM 
10a or 30 µM rapamycin for 48 h. Rapamycin was used as referenc  autophagy control 
at 30 µM treatment. Results are expressed as a mean ± SEM of at least three 

















To further confirm the involvement of autophagy in 8b and 10a induced cell death the 
levels of expression of the autophagy markers Beclin-1 and LC3B were determined. 
Autophagic flux was also assessed by testing SQSTM1/p62 [40]. As shown in Figure 9, 
when MCF-7 cells were treated with 80 µM of either compound for 48 h, Beclin-1, 
LC3B-I and LC3B-II were augmented while SQSTM1/p62 was downregulated thus 
confirming autophagy. Since the activation of AMPK and JNK have been shown to play 
a role in autophagy-mediated cell death [6, 41], AMPK and JNK phosphorylation were 
also studied. As shown in Figure 9, both 8b and 10a induced AMPK and JNK 
phosphorylation. 
 
Figure 9. Beclin-1, p62, LC3B-I, LC3B-II, p-AMPK and p-JNK proteins were 
determined by western blot. (A) A representative experiment is exemplified. (B) 
Aggregate results (mean ± SEM; n=3) expressed as fold induction relative to control 
cells. *p < 0.05, **p < 0.01 and ***p < 0.001.  
 
Inhibition of mTORC1 after AMPK activation is a main step in AMPK-mediated 
autophagy. The PI3K/AKT pathway also has a regulatory effect on mTOR and therefore 















analyze the effect of 8b and 10a on PI3K and AKT signaling, we determined the 
phosphorylation status of both, the PI3K catalytic subunit p110α and AKT (Ser473). As 
shown in Figure 10, increased phospho-p110α and phospho-AKT (Ser473) were 
detected indicating activation of the pathway. PI3K activation is usually related to 
tumor migration enhancement [43] and has been report d to be associated with 
inhibition of autophagy and tumorgenesis [44]. However, in the specific context of 
breast adenocarcinoma cells PI3K activation does not necessarily lead to autophagy 
suppression [45]. Moreover, specific activation of the isoform 1 of AKT in breast, neck 
and head carcinomas has been shown to interfere with their metastatic progression [46, 
47]. Whether AKT-mediated repression of metastasis would represent an additional 
beneficial effect of the treatment with compounds 8b and 10a merits further research. 
 
Figure 10. PI3K and p-AKT proteins were determined by western blot. (A) A 
representative experiment is exemplified. (B) Aggregate results (mean ± SEM; n=3) 


















To sum up, nine diselenide (1a-3a, 5a, 7a-11a) and eight selenocyanate monoamidic 
acids (1b-8b) were synthesized with high yields. A screening in a panel of cancer cell 
lines revealed that MCF-7 was the most sensitive among the tested ones to treatment 
with these compounds. Due to their high potency andstunning selectivity towards 
MCF-7 cells, derivatives 8b and 10a emerged as the most promising structures. Full 
dose response curves in MCF-7 cells showed up a cytostatic effect for these 
compounds. Further analysis uncovered their ability to induce both S phase arrest and a 
caspase-independent cell death program in these cells. Besides, wortmannin and 
chloroquine partially prevented induction of cell death, thus suggesting autophagy. 
Increased levels of Beclin1 and LC3-IIB and reduced levels of SQSTM1/p62 in MCF-7 
cells after exposure to 8b or 10a also supported autophagy. Since pJNK upregulation 
and AMPK phosphorylation were also detected after th  treatments, the modulation of 
the AMPK and JNK signaling pathways seems to be involved in the induction of 
autophagy by 8b and 10a. Finally, the phosphorylation of both, AKT and the PI3K 
catalytic subunit p110α were also detected. Whether the activation of the PI3K/AKT 
pathway by 8b and 10a in MCF-7 cells restricts their invasive capacity and represents 
an extra beneficial effect of these compounds for cancer treatment deserves to be 
studied profoundly. 
 
4. Experimental  
4.1. Chemistry 
4.1.1. Material and methods 
Proton (1H) and carbon (13C) NMR spectra of every compound and selenium (77Se) 















UltrashieldTM spectrometer (Rheinstetten, Germany) using DMSO-d6 as solvent. IR 
spectra were recorded on a Thermo Nicolet FT- IR Nexus spectrophotometer using KBr 
pellets for solid samples. Elemental analysis was performed on a LECO CHN-900 
Elemental Analyzer. Purity of all final compounds was 95% or higher. Chemicals were 
purchased from E. Merck (Darmstadt, Germany), Panreac Química S.A. (Montcada i 
Reixac, Barcelona, Spain), Sigma-Aldrich Quimica, S.A. (Alcobendas, Madrid, Spain) 
and Acros Organics (Janssen Pharmaceuticalaan, Geel, Belgium). 
 
4.1.2. General procedure for the synthesis of compounds 1a-3a, 5a and 7a-8a 
Bis(4-aminophenyl)diselenide (1 mmol) was dissolved in of dry acetone (10 mL) and 
the corresponding anhydride (2.1 mmol) then added. The reaction was then stirred for a 
variable time of 8 h up to 24 h at room temperature. Then reaction was quenched with 
water, compound was filtered and purified by stirring or washing with ethyl ether. 
In order to assign the chemical shifts in NMR spectroscopy the following assignment 
has been done: central rings A and A’, external fragments B and B’ (Figure 10).  
 


















From maleic anhydride. Conditions: 8 h at room temprature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered and then washed with ethyl ether (2 × 
25 mL). A yellow powder was obtained. Yield: 68.9%. Mp: 186–186.5ºC. IR (KBr) cm-
1: 3305, 3193 (N-H), 1723 (C=O carboxylic acid), 1623 (C=O, amide), 818 (Se-Se). 1H
NMR (400 MHz, DMSO-d6) δ: 13.01 (bs, 2H, COOH), 10.54 (s, 2H, NH), 7.60 (d, 4H  
A+A’, J2-3=J6-5= 8.8 Hz, H2+H6), 7.57 (d, 4H, A+A’, J3-2=J5-6= 8.8 Hz, H3+H5), 6.46 (d, 
2H, B+B’, J1-2= 12.0 Hz, H1), 6.31 (d, 2H, B+B’, J2-1= 12.0 Hz, H2). 
13C NMR (100 
MHz, DMSO-d6) δ: 166.76 (COOH), 163.17 (C=O), 138.71 (A+A’, C4), 132.88 (A+A’, 
C2+C6), 131.33+130.23 (B+B’, C1+C2), 124.19 (A+A’, C1), 120.02 (A+A’, C3+C5). MS 
[m/z (% abundance)]: 172 (100), 344 (25). Elemental analysis calculated (%) for 
C20H16N2O6Se2 · 2H2O: C: 41.83, H: 3.51, N: 4.88; found: C: 41.54, H: 3.53, N: 4.80. 
 
4.1.2.2. 2,2’-[(Diselenodiyldibenzene-4,1-diyl)dicarb moyl]bis(benzoic acid) (2a) 
From phthalic anhydride. Conditions: 12 h at room te perature. The product was kept 
under stirring with water (25 mL) for 1 h, filtered and then washed with ethyl ether (2 × 
25 mL). A yellow powder was obtained. Yield: 26.7%. Mp: 154–155ºC. IR (KBr) cm-1: 
3282 (N-H),1708 (C=O carboxylic acid), 1657 (C=O, amide), 819 (Se-Se). 1H NMR 
(400 MHz, DMSO-d6) δ: 11.02 (s, 2H, NH), 7.85 (d, 2H, B+B’, J3-4= 8.8 Hz, H3), 7.72–
7.66 (m, 4H, B+B’, H4+H6), 7.63–7.52 (m, 10H, A+A’, H2+H3+H4+H5, B+B’, H5), 3.39 
(bs, H2O+2COOH). 
13C NMR (100 MHz, DMSO-d6) δ: 171.22 (COOH), 168.50 
(C=O), 140.48 (A+A’, C4), 134.06+132.02 (A+A’, C2+C6+C1), 130.40+130.27 (B+B’, 
C5+C4), 128.65+126.48 (B+B’, C1+C2), 124.60 (A+A’, C3+C5), 121.03+120.51 (B+B’, 
C3+C6). 
77Se NMR (76 MHz, DMSO-d6) δ: 482.83 (Se-Se). MS [m/z (% abundance)]: 
104 (100), 172 (93), 344 (25). Elemental analysis calculated (%) for C28H20N2O6Se2 · 
















4.1.2.3. 4,4’-[Diselenodiylbis(benzene-4,1-diylimino)]bis(4-oxobutanoic acid) (3a) 
From succinic anhydride. Conditions: 24 h at room te perature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A yellow powder was obtained. Yield: 72.27%. Mp: 179–
180ºC. IR (KBr) cm-1: 3318 (NH), 1696 (C=O carboxylic acid), 1666 (C=O, amide), 
818 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.21 (bs, 2H, COOH), 10.11 (s, 2H, 
NH), 7.56 (d, 4H, A+A’, J2-3= J6-5= 8.4 Hz, H2+H6), 7.51 (d, 4H, A+A’, J3-2= J5-6= 8.4 
Hz, H3+H5), 2.60–2.46 (m, 8H, B+B’, H1+H2). 
13C NMR (100 MHz, DMSO-d6) δ: 
174.27 (COOH), 170.80 (C=O), 140.09 (A+A’, C4), 133.76 (A+A’, C2+C6), 123.85 
(A+A’, C1), 120.12 (A+A’, C3+C5), 31.57+29.23 (B+B’, C2+C1). MS [m/z (% 
abundance)]: 172 (100), 344 (15), 424 (10). Elemental analysis calculated (%) for 
C20H20N2O6Se2 · 2H2O: C: 41.51, H: 4.18, N: 4.84; found: C: 41.11, H: 3.79, N: 4.77. 
 
4.1.2.4. 2,2’-[(Diselenodiylbis(benzene-4,1-diylimino)]bis(2-oxoethane-2,1-
diyloxy)diacetic acid (5a) 
From diglycolic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A yellow powder was obtained. Yield: 69.7%. Mp: 140–
141ºC. IR (KBr) cm-1: 3337 (NH), 1709 (C=O carboxylic acid), 1683 (C=O, amide), 
818 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.76 (bs, 2H, COOH), 10.09 (s, 2H, 
NH), 7.62 (d, 4H, A+A’, J2-3= J6-5= 8.5 Hz, H2+H6), 7.55 (d, 4H, A+A’, J3-2= J5-6= 8.5 
Hz, H3+H5), 4.19 (s, 4H, B+B’, H1), 4.17 (s, 4H, B+B’, H2). 
13C NMR (100 MHz, 
DMSO-d6) δ: 172.68 (COOH), 168.99 (C=O), 139.56 (A+A’, C4), 133.94 (A+A’, 















[m/z (% abundance)]: 93 (95), 172 (100). Elemental analysis calculated (%) for 
C20H20N2O8Se2: C: 41.83, H: 3.51, N: 4.88; found: C: 41.83, H: 3.82, N: 5.19. 
 
4.1.2.5. 2,2’-[(Diselenodiyldibenzene-4,1-diyl)dicarb moyl]bis(cyclohexanecarboxylic 
acid) (7a) 
From cis-1,2-cyclohexanecarboxylic anhydride. Conditions: 24 h at room temperature. 
The product was kept under stirring with water (25 mL) for 2 h, filtered, then stirred 
with ethyl ether (100 mL) for 24 h and then filtered. A light brown powder was 
obtained. Yield: 97.7%. Mp: 150–151ºC. IR (KBr) cm-1: 3307 (NH), 1698 (C=O 
carboxylic acid), 1665 (C=O, amide), 820 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 
11.88 (bs, 2H, COOH), 9.87 (s, 2H, NH), 7.55 (d, 4HA+A’, J2-3=J6-5= 8.8 Hz, H2+H6), 
7.50 (d, 4H, A+A’, J3-2=J5-6= 8.8 Hz, H3+H5), 2.93 (d, 2H, B+B’, J1-CHchex= 5.4 Hz, H1), 
2.70–2.56 (m, 2H, B+B’, Hchex), 2.09 (d, 2H, B+B’, JCHchex-1 = 5.4 Hz, Hchex), 1.98 (d, 
2H, B+B’, J= 8.9 Hz, Hchex), 1.83–1.57 (m, 6H, B+B’, 3Hchex), 1.48–1.24 (m, 6H, B+B’, 
3Hchex). 
13C NMR (100 MHz, DMSO-d6) δ: 175.56 (COOH), 173.36 (C=O), 140.42 
(A+A’, C4), 133.78 (A+A’, C2+C6), 123.66 (A+A’, C1), 120.26 (A+A’, C3+C5), 
43.00+42.44 (B+B’, C1+C2), 28.13+25.62+24.47+22.78 (B+B’, C3+C4+C5+C6). MS 
[m/z (% abundance)]:  81 (70), 172 (100), 344 (25). Elemental analysis calculated (%) 
for C28H32N2O6Se2: C: 51.70, H: 4.96, N: 4.31; found: C: 52.06, H: 5.09, N: 4.71. 
 
4.1.2.6. 3,3'-[(Diselenodiyldibenzene-4,1-diyl)dicarb moyl]bis(7-
oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid) (8a) 
From 3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride obtained by the classic procedure 
described for a Diels-Alder reaction using furan and maleic anhydride as reagents to 















kept under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 
mL) for 24 h and then filtered. A yellow powder was obtained. Yield: 22.5%. Mp: 126–
127ºC IR (KBr) cm-1: 3299 (NH), 1706 (C=O carboxylic acid), 1669 (C=O, amide), 819 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.19 (bs, 2H, COOH), 10.03 (s, 2H, NH), 
7.65 (d, 4H, A+A’, J2-3=J6-5= 9.0 Hz, H2+H6), 7.62 (d, 4H, A+A’, J3-2=J5-6= 9.0 Hz, 
H3+H5), 6.50 (s, 4H, B+B’, H3+H5), 5.14 (s, 2H, B+B’, H5), 5.06 (s, 2H, B+B’, H2), 
2.82 (d, 2H, B+B’, J1-6= 9.1 Hz, H1), 2.71 (d, 2H, B+B’, J6-1= 9.1 Hz, H6). 
13C NMR 
(100 MHz, DMSO-d6) δ: 173.08 (COOH), 170.48 (C=O), 141.07 (A+A’, C4), 
137.49+137.08 (B+B’, C4+C5), 135.29 (A+A’, C2+C6), 120.79 (A+A’, C1), 116.51 
(A+A’, C3+C5), 80.82+79.61 (B+B’, C3+C6), 47.96+47.36 (B+B’, C1+C2). MS [m/z (% 
abundance)]: 172 (100), 344 (25). Elemental analysis calculated (%) for C28H24N2O8Se2 
· 2H2O: C: 47.34, H: 3.97, N: 3.94; found: C: 47.66, H: 4.13, N: 4.23. 
 
4.1.3. General procedure for the synthesis of compounds 9a–11a 
A reaction mixture containing 1.3 mmol of the corresponding carboxylic derivatives 
(1a, 2a or 5a) in 15 mL of acetic anhydride and 200 mg of sodium acetate was heated 
for 3 h under reflux, then quenched with water (50 mL) and kept under stirring for 3 h. 
The aqueous solution was extracted with CH2 l2 (2 × 25 mL), dried with sodium 
sulphate anhydrous and the solvent was evaporated under vacuum. 
 
4.1.3.1. 1,1'-(Diselenediyldibenzene-4,1-diyl)bis(1H-pyrrole-2,5-dione) (9a) 
From compound 1a. The product was then washed with n- exane (100 mL). A yellow 
solid was obtained. Yield: 55.4%. Mp: 91.5–92.5ºC. IR (KBr) cm-1: 1710 (C=O), 818 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 7.77 (d, 4H, A+A’, J2-3=J6-5= 8.6 Hz, 
















NMR (100 MHz, DMSO-d6) δ: 169.69 (C=O), 134.75 (A+A’, C4), 131.37+131.27 
(A+A’, C2+C6; B+B’, C1+C2), 129.15 (A+A’, C1), 127.51 (A+A’, C3+C5). MS [m/z (% 
abundance)]: 57 (75), 252 (100), 311 (65). Elemental analysis calculated (%) for 
C20H12N2O4Se2 · H2O: C: 46.17, H: 2.71, N: 5.38; found: C: 46.10, H: 3.03, N: 4.94. 
 
4.1.3.2. 1,1'-(Diselenodiyldibenzene-4,1-diyl)bis(1H-isoindole-1,3(2H)-dione) (10a) 
From compound 2a. The product was then washed with n- exane (100 mL). A yellow 
solid was obtained. Yield: 90.6%. Mp: 248–249ºC. IR (KBr) cm-1: 1709 (C=O), 815 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 8.15–7.79 (m, 12H, A+A’, H2+H6; B+B’, 
H2+H3+H4+H5), 7.55 (d, 4H, A+A’, J3-2=J5-6= 8.4 Hz, H3+H5).
 13C NMR (100 MHz, 
DMSO-d6) δ: 172.73 (C=O), 140.18+140.09 (A+A’, C4; B+B’, C1+C6), 133.49 (B+B’, 
C4+C5), 131.99+131.73 (A+A’, C1+C2+C6), 128.65 (B+B’, C2+C5), 120.26 (A+A’, 
C3+C5). 
77Se NMR (76 MHz, DMSO-d6) δ: 481.88 (Se-Se). MS [m/z (% abundance)]: 
93 (65), 172 (100), 302 (15), 604 (5). Elemental analysis calculated (%) for 
C28H16N2O4Se2 · 2H2O: C: 52.68, H: 3.16, N: 4.39; found: C: 52.82, H: 3.20, N: 4.77. 
 
4.1.3.3. 1,1'-(Diselenodiyldibenzene-4,1-diyl)bis(morpholine-3,5-dione) (11a) 
From compound 5a. The product was then washed with ethyl ether (3 × 10 mL). A 
yellow solid was obtained. Yield: 72.6%. MP: 150–152. IR (KBr) cm-1: 1708 (C=O), 
819 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 7.76 (d, 4H, A+A’, J2-3=J6-5= 7.8 Hz, 
H2+H6), 7.23 (d, 4H, A+A’, J3-2=J5-6= 7.8 Hz, H3+H5), 4.54 (s, 8H, B+B’, H2+H3). 
13C 
NMR (100 MHz, DMSO-d6) δ: 170.19 (C=O), 133.32 (A+A’, C4), 131.42 (A+A’, 
C2+C6), 130.71 (A+A’, C1), 130.30 (A+A’, C3+C5), 67.74 (B+B’, C1+C2). MS [m/z (% 
abundance)]: 184 (100), 271 (25), 538 (15). Elemental analysis calculated (%) for 
















4.1.4. General procedure for the synthesis of compounds 1b–8b 
4-Aminophenyl selenocyanate (2 mmol) was dissolved in ry acetone (15 mL) and the 
corresponding anhydride (2 mmol) then added. The reaction was then stirred for a 
variable time of 12 h up to 48 h at room temperature. Reaction was quenched with 
water, compound was then filtered and purified by stirring or washing with solvents 
such as n-hexane and ethyl ether. The chemical shifts assignment in NMR spectroscopy 
for these compounds is exemplified in Figure 11. 
 
Figure 11. NMR assignation rules followed for series b. 
 
4.1.4.1. (2Z)-4-oxo-4-[(4-selenocyanatophenyl)amino]but-2-enoic acid (1b) 
From maleic anhydride. Conditions: 14 h at room temp rature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered and then washed with n-hexane (25 
mL) and ethyl ether (25 mL). A yellow powder was obtained. Yield: 51.8%. Mp: 161–
162ºC. IR (KBr) cm-1:3299, 3196 (N-H), 2157 (CN), 1722 (C=O carboxylic acid), 1624 
(C=O, amide). 1H NMR (400 MHz, DMSO-d6) δ: 12.96 (s, 1H, COOH), 10.58 (s, 1H, 
NH), 7.69 (bs, 4H, A, H2+H3+H5+H6), 6.47 (d, 1H, B, J1-2= 12.0 Hz, H1), 6.33 (d, 1H, 
B, J2-1= 12.0 Hz, H2). 
13C NMR (100 MHz, DMSO-d6) δ: 167.37 (COOH), 164.02 
(C=O), 140.42 (A, C4), 135.24 (A, C2+C6), 132.04+130.75 (B, C1+C2), 121.16 (A, 
C3+C5), 117.57 (A, C1), 105.77 (CN). 
77Se NMR (76 MHz, DMSO-d6) δ: 322.45 















analysis calculated (%) for C11H8N2O3Se: C: 44.74, H: 2.73, N: 9.49; found: C: 44.35, 
H: 3.08, N: 9.10. 
 
4.1.4.2. 2-[(4-Selenocyanatophenyl)carbamoyl]benzoic ac d (2b) 
From phthalic anhydride. Conditions: 14 h at room te perature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered and then washed with n-hexane (25 
mL) and ethyl ether (25 mL). A white powder was obtained. Yield: 89.5%. Mp: 162–
164ºC. IR (KBr) cm-1: 3317, 3122 (N-H), 2149 (CN), 1718 (C=O carboxylic a id), 
1647 (C=O, amide). 1H NMR (400 MHz, DMSO-d6) δ: 13.14 (s, 1H, COOH), 10.60 (s, 
1H, NH), 7.92 (d, 1H, B, J3-4= 7.5 Hz, H3), 7.78 (d, 2H, A, J2-3=J6-5= 8.3 Hz, H2+H6), 
7.73–7.64 (m, 3H, A, H3+H5, B, H4), 7.62–7.54 (m, 2H, B, H5+H6). 
13C NMR (100 
MHz, DMSO-d6) δ: 168.23 (COOH), 167.80 (C=O), 141.32+139.03 (A, C4; B, C1), 
135.29 (A, C2+C6), 132.31 (B, C5), 130.30+130.09+130.05 (B, C2+C3+C4), 128.25 (B, 
C6), 121.16 (A, C1), 116.99 (A, C3+C5), 105.91 (CN). MS [m/z (% abundance)]: 76 
(50), 104 (55), 118 (100), 198 (20). Elemental analysis calculated (%) for 
C15H10N2O3Se: C: 52.19, H: 2.92, N: 8.11; found: C: 52.06, H: 3.24, N: 8.06. 
 
4.1.4.3. 4-Oxo-4-[(4-selenocyanatophenyl)amino]butanoic acid (3b) 
From succinic anhydride. Conditions: 24 h at room te perature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A brown powder was obtained. Yield: 36.7%. Mp: 154–
156ºC. IR (KBr) cm-1: 3340 (NH), 2158 (CN), 1693 (C=O carboxylic acid), 1636 (C=O, 
amide). 1H NMR (400 MHz, DMSO-d6) δ: 12.18 (bs, 1H, COOH), 10.21 (s, 1H, NH), 
7.66 (bs, 4H, A, H2+H6+H3+H5), 2.58 (d, 2H, A, J2-1= 6.0 Hz, H2), 2.54 (d, 2H, A, J1-2= 
6.0 Hz, H1). 















(A, C4), 135.36 (A, C2+C6), 120.60 (A, C3+C5), 116.47 (A, C1), 105.90 (CN), 31.54 (B, 
C2), 29.10 (B, C1). MS [m/z (% abundance)]: 101 (25), 118 (100), 198 (40), 298 (28). 
Elemental analysis calculated (%) for C11H10N2O3Se2 · H2O: C: 41.92, H: 3.84, N: 8.89; 
found: C: 41.59, H: 3.58, N: 8.69. 
 
4.1.4.4. 3-[(4-Selenocyanatophenyl)carbamoyl]pyrazine-2-carboxylic acid (4b) 
From 2,3-pyrazinedicarboxylic anhydride. Conditions: 24 h at room temperature. The 
product was kept under stirring with water (25 mL) for 3 h, filtered, then stirred with 
ethyl ether (100 mL) for 24 h and then filtered. A yellow powder was obtained. Yield: 
49.3%. Mp: 164–165ºC. IR (KBr) cm-1: 3280 (NH), 2153 (CN), 1765 (C=O carboxylic 
acid), 1671 (C=O, amide). 1H NMR (400 MHz, DMSO-d6) δ: 13.82 (bs, 1H, COOH), 
11.03 (s, 1H, NH), 8.92 (s, 2H, B, H3+H4), 7.87 (d, 2H, A, J2-3=J6-5= 8.6 Hz, H2+H6), 
7.74 (d, 2H, A, J3-2=J5-6= 8.6 Hz, H3+H5). 
13C NMR (100 MHz, DMSO-d6) δ: 167.05 
(COOH), 163.64 (C=O), 146.99+146.75+146.15+145.49 (B, C1+C2+C3+C4), 140.49 (A, 
C4), 135 (A, C2+C6), 122.19 (A, C3+C5), 118 (A, C1), 106.37 (CN). MS [m/z (% 
abundance)]: 79 (100), 107 (95), 118 (30), 304 (75). Elemental analysis calculated (%) 
for C13H8N4O3Se: C: 44.97, H: 2.32, N: 16.14; found: C: 44.73, H: 2.72, N: 15.82. 
 
4.1.4.5. {2-Oxo-2-[(4-selenocyanatophenyl)amino]ethoxy}acetic acid (5b) 
From diglycolic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 1 h, filtered and then washed with ethyl ether (2 × 
25 mL). A white powder was obtained. Yield: 51.1%. Mp: 141–142ºC. IR (KBr) cm-1: 
3305 (NH), 2151 (CN), 1716 (C=O carboxylic acid), 1660 (C=O, amide). 1H NMR (400 
MHz, DMSO-d6) δ: 12.91 (bs, 1H, COOH), 10.14 (s, 1H, NH), 7.74 (d, 2H, A, J2-3=J6-















(s, 2H, B, H2). 
13C NMR (100 MHz, DMSO-d6) δ: 172.25 (COOH), 168.78 (C=O), 
140.14 (A, C4), 135.27 (A, C2+C6), 121.30 (A, C3+C5), 117.43 (A, C1), 105.92 (CN), 
70.83 (B, C1), 68.51 (B, C2). MS [m/z (% abundance)]: 118 (85), 198 (40), 211 (30), 
314 (100). Elemental analysis calculated (%) for C11H10N2O4Se: C: 42.19, H: 3.22, N: 
8.95; found: C: 41.92, H: 3.53, N: 8.82. 
 
4.1.4.6. 2’-[(4-Selenocyanatophenyl)carbamoyl]-[1,1'-biphenyl]-2-carboxylic acid (6b) 
From diphenic anhydride. Conditions: 48 h at room te perature. The product was kept 
under stirring with water (25 mL) for 3 h, filtered and then washed with ethyl ether (2 × 
25 mL). A white powder was obtained. Yield: 21.8%. Mp: 146–147ºC. IR (KBr) cm-1: 
3296 (NH), 2153 (CN), 1726 (C=O, carboxylic acid), 1631 (C=O, amide). 1H NMR 
(400 MHz, DMSO-d6) δ: 12.80 (bs, 1H, COOH), 10.24 (s, 1H, NH), 7.83 (d, 1H  B, J9-
10=7.6 Hz, H9), 7.67–7.58 (m, 3H, B, H2+H5+H12), 7.58–7.48 (m, 5H, A, 
H2+H3+H5+H6, B, H11),7.41 (t, 1H, B, J4-3=J4-5= 7.4 Hz, H4), 7.24 (t, 2H, B, J3-2=J3-
4=J10-9=J10-11= 5.9 Hz, H3+H10). 
13C NMR (100 MHz, DMSO-d6) δ: 169.20 (COOH), 
167.55 (C=O), 141.41 (A, C4), 140.79+140.76 (B, C6+C7), 136.14 (B, C8), 135.19 (A, 
C2+C6), 131.67 (B, C1), 131.42+131.07+130.45+130.11+129.84 (B, 
C2+C3+C4+C9+C11), 127.88+127.78+127.55 (B, C5+C10+C12), 121.06 (A, C3+C5), 
117.14 (A, C1), 105.89 (CN). MS [m/z (% abundance)]: 152 (70), 181 (100), 225 (30), 
422 (10). Elemental analysis calculated (%) for C21H14N2O3Se · 2H2O: C: 55.15, H: 
3.97, N: 6.13; found: C: 55.39, H: 3.59, N: 6.22. 
 
4.1.4.7. 2-[(4-Selenocyanatophenyl)carbamoyl]cyclohexanecarboxylic acid (7b) 
From cis-1,2-cyclohexanecarboxylic anhydride. Conditions: 24 h at room temperature. 















washed with ethyl ether (2 × 25 mL). A white powder was obtained. Yield: 47.0%. Mp: 
150–151ºC. IR (KBr) cm-1: 3335 (NH), 2152 (CN), 1702 (C=O, carboxilic acid), 1677 
(C=O, amide) 1H NMR (400 MHz, DMSO-d6) δ: 11.99 (bs, 1H, COOH), 9.95 (s, 1H, 
NH), 7.66 (d, 2H, A, J2-3=J6-5= 8.5 Hz, H2+H6), 7.62 (d, 2H, A, J3-2=J5-6= 8.5 Hz, 
H3+H5), 2.94 (d, 1H, B, J1-Hchex= 4.0 Hz, H1), 2.60 (d, 1H, B, Jchex-1 = 4.0 Hz, Hchex), 
2.09 (d, 1H, B, J= 9.7 Hz, Hchex), 1.99 (d, 1H, B, J= 8.8 Hz, Hchex), 1.82–1.57 (m, 3H, 
B, 3Hchex), 1.48–1.24 (m, 3H, B, 3Hchex). 13C NMR (100 MHz, DMSO-d6) δ: 175.55 
(COOH), 173.56 (C=O), 141.39 (A, C4), 135.24 (A, C2+C6), 120.76 (A, C3+C5), 116.18 
(A, C1), 105.87 (CN), 43.05+42.42 (B, C1+C2), 28.06+25.64+24.44+22.78 (B, 
C3+C4+C5+C6). MS [m/z (% abundance)]: 67 (90), 81 (93), 118 (100), 198 (60), 334 
(100). Elemental analysis calculated (%) for C15H16N2O3Se · H2O: C: 48.79, H: 4.91, N: 
7.59; found: C: 48.56, H: 4.72, N: 7.66. 
 
4.1.4.8. 3-[(4-Selenocyanatophenyl)carbamoyl]-7-oxabicyclo[2.2.1]hept-5-ene-2-
carboxylic acid (8b) 
From 3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride obtained by the classic procedure 
described for a Diels-Alder reaction using furan and maleic anhydride as reagents to 
yield the Diels-Alder adduct. Conditions: 24 h at room temperature. The product was
kept under stirring with water (25 mL) for 4 h, filtered and then washed with ethyl ether 
(2 × 25 mL). A light-yellow powder was obtained. Yield: 20.3%. Mp: 155–156ºC. IR 
(KBr) cm-1: 3267 (NH), 1711 (C=O carboxylic acid), 1689 (C=O, amide). 1H NMR 
(400 MHz, DMSO-d6) δ: 12.19 (s, 1H, COOH), 10.03 (s, 1H, NH), 7.65 (d, 2H, A, J2-
3=J6-5= 9.0 Hz, H2+H6), 7.62 (d, 2H, A, J3-2=J5-6= 9.0 Hz, H3+H5), 6.50 (s, 2H, B, 
H3+H5), 5.14 (s, 1H, B, H5), 5.06 (s, 1H, B, H2), 2.82 (d, 1H, B, J1-6= 9.1 Hz, H1), 2.71 
(d, 1H, B, J6-1= 9.1 Hz, H6). 















170.48 (C=O), 141.07 (A, C4), 137.49+137.08 (B, C4+C5), 135.29 (A, C2+C6), 120.79 
(A, C3+C5), 116.51 (A, C1), 105.93 (CN), 80.82+79.61 (B, C3+C6), 47.96+47.36 (B, 
C1+C2). 
77Se NMR (76 MHz, DMSO-d6) δ: 320.95 (SeCN). MS [m/z (% abundance)]: 
68 (100), 118 (100), 198 (25), 278 (10). Elemental analysis calculated (%) for 
C15H12N2O4Se · ½ H2O: C: 48.35, H: 3.49, N: 7.52; found: C: 48.30, H: 3.70, N: 7.53. 
 
4.2. Biological evaluation 
4.2.1. Cell cultures 
Cell lines were purchased from the American Type Culture Collection (ATCC). PC-3, 
HTB-54, HT-29, MOLT-4, CCRF-CEM, K-562 and MCF-7 cell lines were grown in 
RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), 
100 units/mL penicillin and 100 mg/mL streptomycin (Gibco). BEAS-2B cell line 
(normal epithelial lung) was cultured in DMEM (Gibco), 10% FBS, 100 units/mL 
penicillin and 100 µg/mL streptomycin. 184B5 cells were grown in DMEM/F12 
medium supplemented with 5% FBS, 1× ITS (Lonza), 100 nM hydrocortisone (Aldich), 
2 mM sodium pyruvate (Lonza), 20 ng/mL EGF (Sigma- Aldrich), 0.3 nM trans-
retinoic acid (Sigma-Aldrich), 100 units/mL penicillin and 100 mg/mL streptomycin. 
Cells were maintained at 37ºC and 5% CO2. 
4.2.2. Cytotoxic and antiproliferative activities 
Cell viability was determined using the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) method at 10 and 100 µM to perform the screening. In order to 
build full dose-response curves five different doses ranging from 0.01 to 100 µM, for 
some compounds lower doses where needed in order to reach 50% cell growth. 
Depending on cell size, 8,000 to 40,000 cells were s eded per well in 96-well plates and 















incubated with 50 µL of MTT (2 mg/mL stock) for 4 h, medium was removed by 
aspiration and formazan crystals dissolved in 150 µL of DMSO. The absorbance was 
measured at 550 nm in a microplate reader (Sunrise reader, Tecan). At least three 
independent experiments performed in quadruplicate were analysed. Results are 
expressed as GI50, the concentration that reduces by 50% the growth of treated cells 
with respect to untreated controls, TGI, the concentration that completely inhibits cell 
growth, and LC50, the concentration that kills 50% of the cells. 
 
4.2.3. Evaluation of cell cycle progression and cell d ath 
A fixed population of MCF-7 cells per flask were seed d in 25 cm2 flasks then 
incubated overnight. Cultures were treated with the corresponding amount of 
compounds 10a, 8b, DMSO (control) or 6 µM camptothecin (positive control). Seeded 
population was dependent on studied time point: 3 × 106 cells/flask for 24 h or shorter 
treatment, 2 × 106 cells/flasks for 48 h treatment and finally 1 × 106 cells/flask for 72 h 
experiments. Apo-Direct kit (BD Pharmigen) was used to determine cell cycle 
distribution and cell death percentage. Cells were fix d in a 1% paraformaldehyde 
solution in PBS for 30‒40 min at 0ºC, washed with PBS twice and incubated for 30 min 
with 70% ethanol on ice. Staining was performed following manufacturer’s protocol 
and samples were analysed by flow cytometry using a Counter Epics XL cytometer 
(Beckman Counter).  
Inhibition assays cells were pre-treated with 50 µM of the pan-caspase inhibitor Z-
VAD-FMK (BD Pharmigen) or 100 nM of the autophagy inhibitor wortmannin (Santa 
Cruz) for 1 h or 10 µM of chloroquine (Sigma Aldrich). The cells were trated with 80 















following the same methodology stated above. At least three independent experiments 
were performed in duplicate.   
4.2.4. Statistical analysis  
Statistical data represent the mean ± SEM of at least three independent experiments 
performed in duplicate. Mann-Whitney U-test was used to stablish statistical 
significance of differences between control and treatment groups. GraphPad Prism 
version 7 was used, significant differences were considered at p < 0.05.  
  
4.2.5. Protein analysis  
Proteins were detected by western blot. Specific antibodies for LC3B, Beclin-1 
(D40C5), SQSTM1/p62, AMPK, JNK, pAKT (Se473) and the PI3K catalytic subunit 
p110α were obtained from Cell Signalling. Anti-actin (H-300) was from Santa Cruz 
Biotechnology. Anti-rabbit IgG conjugated with peroxidase (Cell Signaling) was used 
as secondary antibody. 
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• 17 selenium derivates related to selenocyanates and diselenides were 
synthesized.  
• 8b and 10a were highly selective towards MCF-7 cells. 
• 8b and 10a induce cell cycle arrest in S phase.  
• 8b and 10a modulate AMPK and JNK signaling pathway. 
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Selenocyanates and diselenides are potential antitumor agents. Here we report two 
series of selenium derivatives related to selenocyanates and diselenides containing 
carboxylic, amide and imide moieties. These compounds were screened for their 
potency and selectivity against seven tumor cell lines and two non-malignant cell lines. 
Results showed that MCF-7 cells were especially sensitive to the treatment, with seven 
compounds presenting GI50 values below 10 µM. Notably, the carboxylic selenocyanate 
8b and the cyclic imide 10a also displayed high selectivity for tumor cells. Treatment of 
MCF-7 cells with these compounds resulted in cell cycle arrest at S phase, increased 
levels of pJNK and pAMPK and caspase independent cell death. Autophagy inhibitors 
wortmannin and chloroquine partially prevented 8b and 10a induced cell death. 
Consistent with autophagy, increased Beclin1 and LC3-IIB and reduced SQSTM1/p62 
levels were detected. Our results point to 8b and 10a as autophagic cell death inducers. 

















Despite recent advances in development of anticancer agents, this illness remains a 
leading cause of disease-related death worldwide [1]. Due to their effect on several 
survival or death signaling pathways that may decide the fate of cancer cells [2, 3], 
therapies based on autophagy targeted agents are now in the focus of a wide range of 
researchers. Among the signaling pathways implicated in these processes, JNK 
activation has been proven to participate in multiple autophagic events such as Beclin1 
expression and autophagic-mediated cell death [4, 5].  Energetic stress has also been 
described to be a trigger for autophagy [6]; in this context, AMPK has been proven to 
have an essential role promoting autophagy by inhibiting the mTORs regulatory cascade 
[7]. The phosphorylation of AMPK and JNK in autophagy-mediated cell death has been 
previously described in breast adenocarcinoma  [8, 9] and several other cancer types 
such as myeloma [10] and leukemia [11].  
During the past decade, extensive studies of selenium compounds have demonstrated 
their antitumor and chemopreventive activities in a vast array of experimental models 
[12]. These derivatives interfere with the redox homeostasis and signaling of cancer 
cells. The mechanism by which they cause their effect include alterations in cell cycle 
checkpoints, proliferation, senescence, and death pathways [13]. In addition, some 
selenium derivatives such as selenite, selenocysteine and Se-allylselenocysteine play an 
effective role in cancer treatment as autophagy inducers and modulators of the JNK 
signaling pathway [14-17]. 
Many chemical entities containing selenium, with potent antitumor activity, have been 
explored by the scientific community. Among them, selenocyanate [18] and diselenide 
[19] moieties have been highlighted due to their interesting antitumor properties. In this 















aminophenyl)diselenide (0a) and the corresponding selenocyanate (0b), were recently 
identified in our laboratory [20]. In order to obtain a second generation of selenium 
structures with improved activity, selectivity and water solubility these compounds have 
been used as a starting point to continue with their modulation [21]. It is remarkable that 
one of the limitations of the selenium derivatives is their poor water solubility which is 
detrimental for their bioavailability and drug development. To obtain compounds with 
improved pharmacokinetic properties, modifications in the hydrophobic scaffold that 
improve water solubility are usually assayed. As an example of this strategy, 
introduction of a hydroxyl group in the phenyl ring of the natural product camptothecin 
has been shown to counteract efficiently this drawback [22]. Thus, a useful option when 
using this approach is to incorporate polar functional groups, such as acidic or basic 
groups. These fragments enable the possibility of salt formation and therefore might 
enhance water solubility [23, 24]. In this study, substantial efforts had been directed 
towards finding different chemical scaffolds that, while maintaining the cytotoxic 
activity, should increase the hydrophilicity further contributing to the solubility 
optimization. Among the structural features incorporated, we surmised that the 
introduction of the carboxylic core could be a logical approach for improving its 
aqueous solubility. This moiety is present in widely described organoselenium 
compounds such as 3,3’-diselenodipropionic acid [25]. In addition, the dicarboxylic 
acids are of special importance because of their versatility in the preparation of the 
corresponding cyclic imide homologs which are widely described in the literature as 
potential antitumor agents [26, 27].  
Taking into consideration the facts stated above and our previous work in the field of 
new selenium compounds as antitumor agents [21, 28-33], the present study aimed to 
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derived from non-malignant tissue. Evaluation was performed at 48 h treatment 
following the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
methodology as previously described [33]. The cancer cell lines included in the panel 
were PC-3 (prostatic adenocarcinoma); HTB-54 (lung carcinoma), and HT-29 (colon 
carcinoma); MOLT-4 and CCRF-CEM (acute lymphoblastic leukemia); K-562 (chronic 
myelogenous leukemia) and MCF-7 (breast adenocarcinoma). The selected cell lines 
derived from non-malignant tissue were 184B5 and BEAS-2B. Cisplatin was used as 
positive control. In addition, the parent compounds bis(4-aminophenyl)diselenide (0a) 
and 4-aminophenylselenocyanate (0b) were tested as a reference to identify whether the 
second generation compounds accomplished the objective of improving potency and 
selectivity.  
To narrow down the number of derivatives moving on to the full dose-response 
cytotoxic profiling assay, a two-dose concentration (100 μM and 10 μM) screening was 
first performed. The results obtained for the 10 μM treatment are shown in Figure 4. As 
shown in the figure, MCF-7 cells were the most sensitive cells toward the tested 
derivatives. In fact, seven compounds (1b, 2b, 4b, 8a, 8b, 9a and 10a) reduced cell 
growth to less than 50% when assayed at 10 μM in these cells. Some compounds also 
matched this threshold in PC-3, CCRF-CEM, HTB-54, MOLT-4 and HT-29 cells. 
However, none of the derivatives was able to reduce the cell growth effectively in K-
562, the most resistant cell line to the treatments. Interestingly, compounds 1b, 2b, 4b, 
8a, 8b, 9a and 10a did not significantly affect cell growth in 184B5 cells, thus 
suggesting a potential selectivity of the compounds for breast cancer cells. 
Consequently, those seven compounds were further analysed in full dose-response 















are shown in Table 1. Selectivity for tumor cells was estimated according to the 
formulas GI50 (184B5)/GI50 (MCF-7) and GI50 (BEAS-2B)/GI50(HTB-54) (Table 2).  
 
  

































































































































































































































































Figure 4. Heat map representing average percentages of cell growth for every 















Table 1. Average values of GI50, TGI and LD50 (μM) for 48 h treatment. 
Code 
PC-3 HTB-54 HT-29 MOLT-4 CCRF-CEM K-562 MCF-7 
GI50


































































































































































0b 1.02 1.54 2.30 0.87 1.00 1.13 0.27 1.11 5.28 3.33 3.39 3.42 1.71 2.74 4.43 1.03 1.29 1.58 1.00 1.48 2.20 
0a 0.80 1.62 2.98 0.21 0.80 2.16 
<0.0
1 
1.78 8.37 3.84 5.95 8.06 5.28 16.87 42.82 0.95 1.19 1.48 0.75 0.96 1.16 
Cisplatin
* 
5.01 50.1 >100 n.d.# n.d.# n.d.# 7.94 >100 >100 1.58 
63.1
0 
>100 1.00 79.43 >100 5.01 >100 >100 3.16 >100 >100 
a GI50, concentration that reduces growth by 50% compared to control. 
b TGI, concentration that completely inhibits cell growth. c LC50, 

















Table 2. Average values of GI50, TGI and LD50 (μM) for 48 h treatment and 
calculated SI. 
 
a Selectivity index (SI) calculated as GI50 (184B5)/GI50 (MCF-7). 
b SI calculated as GI50 
(BEAS-2B)/GI50(HTB-54). 
 
As shown in Tables 1 and 2, derivatives 8a, 9a and 10a exhibited GI50 values under 10 
μM in three of the tested cancer cell lines. Besides, compounds 1b, 2b, 4b, 8b and 10a 
were highly selective for tumor cells in the breast model. Remarkably, though highly 
cytotoxic, parent compounds 0a and 0b showed low selectivity for breast cancer cells 
(SI < 9). Therefore, we decided to focus on the effects of these compounds in the breast 
cancer cell line. When ranked in terms of potency and selectivity for breast cancer cells, 







 TGI GI50 GI50 TGI LD50 
1b >100 >100 >100 >51.73 10.45 42.82 80.15 0.22 
2b >100 >100 >100 >12.98 4.43 24.63 >100 <0.39 
4b >100 >100 >100 15.46 52.93 >100 >100 <0.16 
8a 8.93 11.25 15.67 1.19 1.05 4.43 15.53 0.04 
8b 77.25 91.19 >100 23.19 15.82 51.02 77.25 0.33 
9a 40.51 63.07 86.29 6.74 1.97 43.62 73.77 0.24 
10a 60.78 >100 > 100 6.3×104 0.75 20.86 61.91 0.15 
0a 6.29 14.03 30.44 8.39 0.73 0.88 1.09 3.44 















SI, as the leader structure. Despite less cytotoxic, 1b and 8b were also highly selective. 
Among them, the analog derivative of norcantharidin (8b) was selected in order to 
evaluate whether this structure was able to mimic norcantharidin’s effect and induce 
autophagy. As a result, derivatives 8b and 10a were selected to further analyse their 
mechanism of action in MCF-7 cells. As only the highest concentration tested led to 
negative growth values as exemplified on Figure 5, these results uncover a mainly 
cytostatic profile.  
   
Figure 5. Dose response curves obtained for 8b (A) and 10a (B) in MCF-7 and 
MDA-MB-231 cell lines.  
 
Besides, comparison between 10a and 0a clearly showed a great enhancement in 
selectivity for the second generation compound. In fact, SI was 7,000 times higher for 
compound 10a than for 0a, its parent compound. This effect was less notorious when 
compound 8b was compared with 0b. However, both 10a and 8b succeeded in 
increasing the selectivity towards the cancer cells, thus meeting one of our goals.  
The importance of estrogen receptors (ER) in cell cycle and cell proliferation in breast 
cancer cells, as well as the crucial role of estradiol synthesis pathways has been widely 
described. In fact, antiestrogens have been found to repress transcription of several ERα 
target genes in MCF-7 cells, specifically in S phase [35]. Besides, when MCF-7 cell 


















































cultures were exposed to a genotoxic agent higher levels of DNA damage in S- and 
G2/M-enriched cultures correlated with higher levels of CYP1A1 y CYP1B1 [36]. 
MCF-7 is an ERα expressing cell line. Therefore, to compare we decided to test 8b and 
10a in MDA-MB-231, a breast cancer cell line non-expressing ERα. Obtained results 
for MDA-MB-231 cells are shown in Figure 5. As shown in the figure, 8a and 10a 
dose-response curves in MDA-MB-231differ from those obtained in MCF-7 cells. 
Moreover, lying in the micromolar range GI50, TGI and LD50 values for 8b (GI50= 33.61 
μM, TGI= 61.92 μM and LD50= 83.92 μM) and 10a (GI50= 13.65 μM, TGI= 51.49 μM 
and LD50> 100 μM) are also higher than in MCF-7cells. These data suggest that ER 
signalling and/or estradiol metabolism play a relevant role in cytostatic effect displayed 
by 8b and 10a in MCF-7 cells.  
In terms of structure-activity relationship, most diselenide structures containing 
carboxylic moieties were discarded in the screening process. For instance, when 
comparing 8b with its diselenide homolog a complete loss of selectivity could be 
observed. On the other hand, if we stablish a comparison between carboxylic 
derivatives and their cyclic imide homologs data suggests that this modification was 
crucial for both potency and selectivity.  
2.2.2. Compounds 8b and 10a induce cell cycle arrest in S phase and cell death  
Many selenium containing compounds involve cell cycle regulation among their 
therapeutic effects [13]. Therefore, as a first approach to the mechanism of action we 
studied the effect of 8b and 10a on cell cycle. With this purpose, the cell cycle status of 
MCF-7 cell cultures treated with different concentrations of 8b and 10a and for 
different time points was determined by flow cytometry. Camptothecin was used as 
positive control. As shown in the Figure 6, both a reduction in the number of G0/G1 
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To sum up, nine diselenide (1a-3a, 5a, 7a-11a) and eight selenocyanate monoamidic 
acids (1b-8b) were synthesized with high yields. A screening in a panel of cancer cell 
lines revealed that MCF-7 was the most sensitive among the tested ones to treatment 
with these compounds. Due to their high potency and stunning selectivity towards 
MCF-7 cells, derivatives 8b and 10a emerged as the most promising structures. Full 
dose response curves in MCF-7 cells showed up a cytostatic effect for these 
compounds. Further analysis uncovered their ability to induce both S phase arrest and a 
caspase-independent cell death program in these cells. Besides, wortmannin and 
chloroquine partially prevented induction of cell death, thus suggesting autophagy. 
Increased levels of Beclin1 and LC3-IIB and reduced levels of SQSTM1/p62 in MCF-7 
cells after exposure to 8b or 10a also supported autophagy. Since pJNK upregulation 
and AMPK phosphorylation were also detected after the treatments, the modulation of 
the AMPK and JNK signaling pathways seems to be involved in the induction of 
autophagy by 8b and 10a. Finally, the phosphorylation of both, AKT and the PI3K 
catalytic subunit p110α were also detected. Whether the activation of the PI3K/AKT 
pathway by 8b and 10a in MCF-7 cells restricts their invasive capacity and represents 
an extra beneficial effect of these compounds for cancer treatment deserves to be 
studied profoundly. 
 
4. Experimental  
4.1. Chemistry 
4.1.1. Material and methods 
Proton (1H) and carbon (13C) NMR spectra of every compound and selenium (77Se) 
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From maleic anhydride. Conditions: 8 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered and then washed with ethyl ether (2 × 
25 mL). A yellow powder was obtained. Yield: 68.9%. Mp: 186–186.5ºC. IR (KBr) cm-
1: 3305, 3193 (N-H), 1723 (C=O carboxylic acid), 1623 (C=O, amide), 818 (Se-Se). 1H 
NMR (400 MHz, DMSO-d6) δ: 13.01 (bs, 2H, COOH), 10.54 (s, 2H, NH), 7.60 (d, 4H, 
A+A’, J2-3=J6-5= 8.8 Hz, H2+H6), 7.57 (d, 4H, A+A’, J3-2=J5-6= 8.8 Hz, H3+H5), 6.46 (d, 
2H, B+B’, J1-2= 12.0 Hz, H1), 6.31 (d, 2H, B+B’, J2-1= 12.0 Hz, H2). 
13C NMR (100 
MHz, DMSO-d6) δ: 166.76 (COOH), 163.17 (C=O), 138.71 (A+A’, C4), 132.88 (A+A’, 
C2+C6), 131.33+130.23 (B+B’, C1+C2), 124.19 (A+A’, C1), 120.02 (A+A’, C3+C5). MS 
[m/z (% abundance)]: 172 (100), 344 (25). Elemental analysis calculated (%) for 
C20H16N2O6Se2 · 2H2O: C: 41.83, H: 3.51, N: 4.88; found: C: 41.54, H: 3.53, N: 4.80. 
 
4.1.2.2. 2,2’-[(Diselenodiyldibenzene-4,1-diyl)dicarbamoyl]bis(benzoic acid) (2a) 
From phthalic anhydride. Conditions: 12 h at room temperature. The product was kept 
under stirring with water (25 mL) for 1 h, filtered and then washed with ethyl ether (2 × 
25 mL). A yellow powder was obtained. Yield: 26.7%. Mp: 154–155ºC. IR (KBr) cm-1: 
3282 (N-H),1708 (C=O carboxylic acid), 1657 (C=O, amide), 819 (Se-Se). 1H NMR 
(400 MHz, DMSO-d6) δ: 11.02 (s, 2H, NH), 7.85 (d, 2H, B+B’, J3-4= 8.8 Hz, H3), 7.72–
7.66 (m, 4H, B+B’, H4+H6), 7.63–7.52 (m, 10H, A+A’, H2+H3+H4+H5, B+B’, H5), 3.39 
(bs, H2O+2COOH). 
13C NMR (100 MHz, DMSO-d6) δ: 171.22 (COOH), 168.50 
(C=O), 140.48 (A+A’, C4), 134.06+132.02 (A+A’, C2+C6+C1), 130.40+130.27 (B+B’, 
C5+C4), 128.65+126.48 (B+B’, C1+C2), 124.60 (A+A’, C3+C5), 121.03+120.51 (B+B’, 
C3+C6). 
77Se NMR (76 MHz, DMSO-d6) δ: 482.83 (Se-Se). MS [m/z (% abundance)]: 
104 (100), 172 (93), 344 (25). Elemental analysis calculated (%) for C28H20N2O6Se2 · 
















4.1.2.3. 4,4’-[Diselenodiylbis(benzene-4,1-diylimino)]bis(4-oxobutanoic acid) (3a) 
From succinic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A yellow powder was obtained. Yield: 72.27%. Mp: 179–
180ºC. IR (KBr) cm-1: 3318 (NH), 1696 (C=O carboxylic acid), 1666 (C=O, amide), 
818 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.21 (bs, 2H, COOH), 10.11 (s, 2H, 
NH), 7.56 (d, 4H, A+A’, J2-3= J6-5= 8.4 Hz, H2+H6), 7.51 (d, 4H, A+A’, J3-2= J5-6= 8.4 
Hz, H3+H5), 2.60–2.46 (m, 8H, B+B’, H1+H2). 
13C NMR (100 MHz, DMSO-d6) δ: 
174.27 (COOH), 170.80 (C=O), 140.09 (A+A’, C4), 133.76 (A+A’, C2+C6), 123.85 
(A+A’, C1), 120.12 (A+A’, C3+C5), 31.57+29.23 (B+B’, C2+C1). MS [m/z (% 
abundance)]: 172 (100), 344 (15), 424 (10). Elemental analysis calculated (%) for 
C20H20N2O6Se2 · 2H2O: C: 41.51, H: 4.18, N: 4.84; found: C: 41.11, H: 3.79, N: 4.77. 
 
4.1.2.4. 2,2’-[(Diselenodiylbis(benzene-4,1-diylimino)]bis(2-oxoethane-2,1-
diyloxy)diacetic acid (5a) 
From diglycolic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A yellow powder was obtained. Yield: 69.7%. Mp: 140–
141ºC. IR (KBr) cm-1: 3337 (NH), 1709 (C=O carboxylic acid), 1683 (C=O, amide), 
818 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.76 (bs, 2H, COOH), 10.09 (s, 2H, 
NH), 7.62 (d, 4H, A+A’, J2-3= J6-5= 8.5 Hz, H2+H6), 7.55 (d, 4H, A+A’, J3-2= J5-6= 8.5 
Hz, H3+H5), 4.19 (s, 4H, B+B’, H1), 4.17 (s, 4H, B+B’, H2). 
13C NMR (100 MHz, 
DMSO-d6) δ: 172.68 (COOH), 168.99 (C=O), 139.56 (A+A’, C4), 133.94 (A+A’, 















[m/z (% abundance)]: 93 (95), 172 (100). Elemental analysis calculated (%) for 




From cis-1,2-cyclohexanecarboxylic anhydride. Conditions: 24 h at room temperature. 
The product was kept under stirring with water (25 mL) for 2 h, filtered, then stirred 
with ethyl ether (100 mL) for 24 h and then filtered. A light brown powder was 
obtained. Yield: 97.7%. Mp: 150–151ºC. IR (KBr) cm-1: 3307 (NH), 1698 (C=O 
carboxylic acid), 1665 (C=O, amide), 820 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 
11.88 (bs, 2H, COOH), 9.87 (s, 2H, NH), 7.55 (d, 4H, A+A’, J2-3=J6-5= 8.8 Hz, H2+H6), 
7.50 (d, 4H, A+A’, J3-2=J5-6= 8.8 Hz, H3+H5), 2.93 (d, 2H, B+B’, J1-CHchex= 5.4 Hz, H1), 
2.70–2.56 (m, 2H, B+B’, Hchex), 2.09 (d, 2H, B+B’, JCHchex-1 = 5.4 Hz, Hchex), 1.98 (d, 
2H, B+B’, J= 8.9 Hz, Hchex), 1.83–1.57 (m, 6H, B+B’, 3Hchex), 1.48–1.24 (m, 6H, B+B’, 
3Hchex). 
13C NMR (100 MHz, DMSO-d6) δ: 175.56 (COOH), 173.36 (C=O), 140.42 
(A+A’, C4), 133.78 (A+A’, C2+C6), 123.66 (A+A’, C1), 120.26 (A+A’, C3+C5), 
43.00+42.44 (B+B’, C1+C2), 28.13+25.62+24.47+22.78 (B+B’, C3+C4+C5+C6). MS 
[m/z (% abundance)]:  81 (70), 172 (100), 344 (25). Elemental analysis calculated (%) 
for C28H32N2O6Se2: C: 51.70, H: 4.96, N: 4.31; found: C: 52.06, H: 5.09, N: 4.71. 
 
4.1.2.6. 3,3'-[(Diselenodiyldibenzene-4,1-diyl)dicarbamoyl]bis(7-
oxabicyclo[2.2.1]hept-5-ene-2-carboxylic acid) (8a) 
From 3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride obtained by the classic procedure 
described for a Diels-Alder reaction using furan and maleic anhydride as reagents to 















kept under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 
mL) for 24 h and then filtered. A yellow powder was obtained. Yield: 22.5%. Mp: 126–
127ºC IR (KBr) cm-1: 3299 (NH), 1706 (C=O carboxylic acid), 1669 (C=O, amide), 819 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 12.19 (bs, 2H, COOH), 10.03 (s, 2H, NH), 
7.65 (d, 4H, A+A’, J2-3=J6-5= 9.0 Hz, H2+H6), 7.62 (d, 4H, A+A’, J3-2=J5-6= 9.0 Hz, 
H3+H5), 6.50 (s, 4H, B+B’, H3+H5), 5.14 (s, 2H, B+B’, H5), 5.06 (s, 2H, B+B’, H2), 
2.82 (d, 2H, B+B’, J1-6= 9.1 Hz, H1), 2.71 (d, 2H, B+B’, J6-1= 9.1 Hz, H6). 
13C NMR 
(100 MHz, DMSO-d6) δ: 173.08 (COOH), 170.48 (C=O), 141.07 (A+A’, C4), 
137.49+137.08 (B+B’, C4+C5), 135.29 (A+A’, C2+C6), 120.79 (A+A’, C1), 116.51 
(A+A’, C3+C5), 80.82+79.61 (B+B’, C3+C6), 47.96+47.36 (B+B’, C1+C2). MS [m/z (% 
abundance)]: 172 (100), 344 (25). Elemental analysis calculated (%) for C28H24N2O8Se2 
· 2H2O: C: 47.34, H: 3.97, N: 3.94; found: C: 47.66, H: 4.13, N: 4.23. 
 
4.1.3. General procedure for the synthesis of compounds 9a–11a 
A reaction mixture containing 1.3 mmol of the corresponding carboxylic derivatives 
(1a, 2a or 5a) in 15 mL of acetic anhydride and 200 mg of sodium acetate was heated 
for 3 h under reflux, then quenched with water (50 mL) and kept under stirring for 3 h. 
The aqueous solution was extracted with CH2Cl2 (2 × 25 mL), dried with sodium 
sulphate anhydrous and the solvent was evaporated under vacuum. 
 
4.1.3.1. 1,1'-(Diselenediyldibenzene-4,1-diyl)bis(1H-pyrrole-2,5-dione) (9a) 
From compound 1a. The product was then washed with n-hexane (100 mL). A yellow 
solid was obtained. Yield: 55.4%. Mp: 91.5–92.5ºC. IR (KBr) cm-1: 1710 (C=O), 818 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 7.77 (d, 4H, A+A’, J2-3=J6-5= 8.6 Hz, 
















NMR (100 MHz, DMSO-d6) δ: 169.69 (C=O), 134.75 (A+A’, C4), 131.37+131.27 
(A+A’, C2+C6; B+B’, C1+C2), 129.15 (A+A’, C1), 127.51 (A+A’, C3+C5). MS [m/z (% 
abundance)]: 57 (75), 252 (100), 311 (65). Elemental analysis calculated (%) for 
C20H12N2O4Se2 · H2O: C: 46.17, H: 2.71, N: 5.38; found: C: 46.10, H: 3.03, N: 4.94. 
 
4.1.3.2. 1,1'-(Diselenodiyldibenzene-4,1-diyl)bis(1H-isoindole-1,3(2H)-dione) (10a) 
From compound 2a. The product was then washed with n-hexane (100 mL). A yellow 
solid was obtained. Yield: 90.6%. Mp: 248–249ºC. IR (KBr) cm-1: 1709 (C=O), 815 
(Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 8.15–7.79 (m, 12H, A+A’, H2+H6; B+B’, 
H2+H3+H4+H5), 7.55 (d, 4H, A+A’, J3-2=J5-6= 8.4 Hz, H3+H5).
 13C NMR (100 MHz, 
DMSO-d6) δ: 172.73 (C=O), 140.18+140.09 (A+A’, C4; B+B’, C1+C6), 133.49 (B+B’, 
C4+C5), 131.99+131.73 (A+A’, C1+C2+C6), 128.65 (B+B’, C2+C5), 120.26 (A+A’, 
C3+C5). 
77Se NMR (76 MHz, DMSO-d6) δ: 481.88 (Se-Se). MS [m/z (% abundance)]: 
93 (65), 172 (100), 302 (15), 604 (5). Elemental analysis calculated (%) for 
C28H16N2O4Se2 · 2H2O: C: 52.68, H: 3.16, N: 4.39; found: C: 52.82, H: 3.20, N: 4.77. 
 
4.1.3.3. 1,1'-(Diselenodiyldibenzene-4,1-diyl)bis(morpholine-3,5-dione) (11a) 
From compound 5a. The product was then washed with ethyl ether (3 × 10 mL). A 
yellow solid was obtained. Yield: 72.6%. MP: 150–152. IR (KBr) cm-1: 1708 (C=O), 
819 (Se-Se). 1H NMR (400 MHz, DMSO-d6) δ: 7.76 (d, 4H, A+A’, J2-3=J6-5= 7.8 Hz, 
H2+H6), 7.23 (d, 4H, A+A’, J3-2=J5-6= 7.8 Hz, H3+H5), 4.54 (s, 8H, B+B’, H2+H3). 
13C 
NMR (100 MHz, DMSO-d6) δ: 170.19 (C=O), 133.32 (A+A’, C4), 131.42 (A+A’, 
C2+C6), 130.71 (A+A’, C1), 130.30 (A+A’, C3+C5), 67.74 (B+B’, C1+C2). MS [m/z (% 
abundance)]: 184 (100), 271 (25), 538 (15). Elemental analysis calculated (%) for 
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analysis calculated (%) for C11H8N2O3Se: C: 44.74, H: 2.73, N: 9.49; found: C: 44.35, 
H: 3.08, N: 9.10. 
 
4.1.4.2. 2-[(4-Selenocyanatophenyl)carbamoyl]benzoic acid (2b) 
From phthalic anhydride. Conditions: 14 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered and then washed with n-hexane (25 
mL) and ethyl ether (25 mL). A white powder was obtained. Yield: 89.5%. Mp: 162–
164ºC. IR (KBr) cm-1: 3317, 3122 (N-H), 2149 (CN), 1718 (C=O carboxylic acid), 
1647 (C=O, amide). 1H NMR (400 MHz, DMSO-d6) δ: 13.14 (s, 1H, COOH), 10.60 (s, 
1H, NH), 7.92 (d, 1H, B, J3-4= 7.5 Hz, H3), 7.78 (d, 2H, A, J2-3=J6-5= 8.3 Hz, H2+H6), 
7.73–7.64 (m, 3H, A, H3+H5, B, H4), 7.62–7.54 (m, 2H, B, H5+H6). 
13C NMR (100 
MHz, DMSO-d6) δ: 168.23 (COOH), 167.80 (C=O), 141.32+139.03 (A, C4; B, C1), 
135.29 (A, C2+C6), 132.31 (B, C5), 130.30+130.09+130.05 (B, C2+C3+C4), 128.25 (B, 
C6), 121.16 (A, C1), 116.99 (A, C3+C5), 105.91 (CN). MS [m/z (% abundance)]: 76 
(50), 104 (55), 118 (100), 198 (20). Elemental analysis calculated (%) for 
C15H10N2O3Se: C: 52.19, H: 2.92, N: 8.11; found: C: 52.06, H: 3.24, N: 8.06. 
 
4.1.4.3. 4-Oxo-4-[(4-selenocyanatophenyl)amino]butanoic acid (3b) 
From succinic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 2 h, filtered, then stirred with ethyl ether (100 mL) 
for 24 h and then filtered. A brown powder was obtained. Yield: 36.7%. Mp: 154–
156ºC. IR (KBr) cm-1: 3340 (NH), 2158 (CN), 1693 (C=O carboxylic acid), 1636 (C=O, 
amide). 1H NMR (400 MHz, DMSO-d6) δ: 12.18 (bs, 1H, COOH), 10.21 (s, 1H, NH), 
7.66 (bs, 4H, A, H2+H6+H3+H5), 2.58 (d, 2H, A, J2-1= 6.0 Hz, H2), 2.54 (d, 2H, A, J1-2= 
6.0 Hz, H1). 















(A, C4), 135.36 (A, C2+C6), 120.60 (A, C3+C5), 116.47 (A, C1), 105.90 (CN), 31.54 (B, 
C2), 29.10 (B, C1). MS [m/z (% abundance)]: 101 (25), 118 (100), 198 (40), 298 (28). 
Elemental analysis calculated (%) for C11H10N2O3Se2 · H2O: C: 41.92, H: 3.84, N: 8.89; 
found: C: 41.59, H: 3.58, N: 8.69. 
 
4.1.4.4. 3-[(4-Selenocyanatophenyl)carbamoyl]pyrazine-2-carboxylic acid (4b) 
From 2,3-pyrazinedicarboxylic anhydride. Conditions: 24 h at room temperature. The 
product was kept under stirring with water (25 mL) for 3 h, filtered, then stirred with 
ethyl ether (100 mL) for 24 h and then filtered. A yellow powder was obtained. Yield: 
49.3%. Mp: 164–165ºC. IR (KBr) cm-1: 3280 (NH), 2153 (CN), 1765 (C=O carboxylic 
acid), 1671 (C=O, amide). 1H NMR (400 MHz, DMSO-d6) δ: 13.82 (bs, 1H, COOH), 
11.03 (s, 1H, NH), 8.92 (s, 2H, B, H3+H4), 7.87 (d, 2H, A, J2-3=J6-5= 8.6 Hz, H2+H6), 
7.74 (d, 2H, A, J3-2=J5-6= 8.6 Hz, H3+H5). 
13C NMR (100 MHz, DMSO-d6) δ: 167.05 
(COOH), 163.64 (C=O), 146.99+146.75+146.15+145.49 (B, C1+C2+C3+C4), 140.49 (A, 
C4), 135 (A, C2+C6), 122.19 (A, C3+C5), 118 (A, C1), 106.37 (CN). MS [m/z (% 
abundance)]: 79 (100), 107 (95), 118 (30), 304 (75). Elemental analysis calculated (%) 
for C13H8N4O3Se: C: 44.97, H: 2.32, N: 16.14; found: C: 44.73, H: 2.72, N: 15.82. 
 
4.1.4.5. {2-Oxo-2-[(4-selenocyanatophenyl)amino]ethoxy}acetic acid (5b) 
From diglycolic anhydride. Conditions: 24 h at room temperature. The product was kept 
under stirring with water (25 mL) for 1 h, filtered and then washed with ethyl ether (2 × 
25 mL). A white powder was obtained. Yield: 51.1%. Mp: 141–142ºC. IR (KBr) cm-1: 
3305 (NH), 2151 (CN), 1716 (C=O carboxylic acid), 1660 (C=O, amide). 1H NMR (400 
MHz, DMSO-d6) δ: 12.91 (bs, 1H, COOH), 10.14 (s, 1H, NH), 7.74 (d, 2H, A, J2-3=J6-















(s, 2H, B, H2). 
13C NMR (100 MHz, DMSO-d6) δ: 172.25 (COOH), 168.78 (C=O), 
140.14 (A, C4), 135.27 (A, C2+C6), 121.30 (A, C3+C5), 117.43 (A, C1), 105.92 (CN), 
70.83 (B, C1), 68.51 (B, C2). MS [m/z (% abundance)]: 118 (85), 198 (40), 211 (30), 
314 (100). Elemental analysis calculated (%) for C11H10N2O4Se: C: 42.19, H: 3.22, N: 
8.95; found: C: 41.92, H: 3.53, N: 8.82. 
 
4.1.4.6. 2’-[(4-Selenocyanatophenyl)carbamoyl]-[1,1'-biphenyl]-2-carboxylic acid (6b) 
From diphenic anhydride. Conditions: 48 h at room temperature. The product was kept 
under stirring with water (25 mL) for 3 h, filtered and then washed with ethyl ether (2 × 
25 mL). A white powder was obtained. Yield: 21.8%. Mp: 146–147ºC. IR (KBr) cm-1: 
3296 (NH), 2153 (CN), 1726 (C=O, carboxylic acid), 1631 (C=O, amide). 1H NMR 
(400 MHz, DMSO-d6) δ: 12.80 (bs, 1H, COOH), 10.24 (s, 1H, NH), 7.83 (d, 1H, B, J9-
10=7.6 Hz, H9), 7.67–7.58 (m, 3H, B, H2+H5+H12), 7.58–7.48 (m, 5H, A, 
H2+H3+H5+H6, B, H11),7.41 (t, 1H, B, J4-3=J4-5= 7.4 Hz, H4), 7.24 (t, 2H, B, J3-2=J3-
4=J10-9=J10-11= 5.9 Hz, H3+H10). 
13C NMR (100 MHz, DMSO-d6) δ: 169.20 (COOH), 
167.55 (C=O), 141.41 (A, C4), 140.79+140.76 (B, C6+C7), 136.14 (B, C8), 135.19 (A, 
C2+C6), 131.67 (B, C1), 131.42+131.07+130.45+130.11+129.84 (B, 
C2+C3+C4+C9+C11), 127.88+127.78+127.55 (B, C5+C10+C12), 121.06 (A, C3+C5), 
117.14 (A, C1), 105.89 (CN). MS [m/z (% abundance)]: 152 (70), 181 (100), 225 (30), 
422 (10). Elemental analysis calculated (%) for C21H14N2O3Se · 2H2O: C: 55.15, H: 
3.97, N: 6.13; found: C: 55.39, H: 3.59, N: 6.22. 
 
4.1.4.7. 2-[(4-Selenocyanatophenyl)carbamoyl]cyclohexanecarboxylic acid (7b) 
From cis-1,2-cyclohexanecarboxylic anhydride. Conditions: 24 h at room temperature. 















washed with ethyl ether (2 × 25 mL). A white powder was obtained. Yield: 47.0%. Mp: 
150–151ºC. IR (KBr) cm-1: 3335 (NH), 2152 (CN), 1702 (C=O, carboxilic acid), 1677 
(C=O, amide) 1H NMR (400 MHz, DMSO-d6) δ: 11.99 (bs, 1H, COOH), 9.95 (s, 1H, 
NH), 7.66 (d, 2H, A, J2-3=J6-5= 8.5 Hz, H2+H6), 7.62 (d, 2H, A, J3-2=J5-6= 8.5 Hz, 
H3+H5), 2.94 (d, 1H, B, J1-Hchex= 4.0 Hz, H1), 2.60 (d, 1H, B, Jchex-1 = 4.0 Hz, Hchex), 
2.09 (d, 1H, B, J= 9.7 Hz, Hchex), 1.99 (d, 1H, B, J= 8.8 Hz, Hchex), 1.82–1.57 (m, 3H, 
B, 3Hchex), 1.48–1.24 (m, 3H, B, 3Hchex). 13C NMR (100 MHz, DMSO-d6) δ: 175.55 
(COOH), 173.56 (C=O), 141.39 (A, C4), 135.24 (A, C2+C6), 120.76 (A, C3+C5), 116.18 
(A, C1), 105.87 (CN), 43.05+42.42 (B, C1+C2), 28.06+25.64+24.44+22.78 (B, 
C3+C4+C5+C6). MS [m/z (% abundance)]: 67 (90), 81 (93), 118 (100), 198 (60), 334 
(100). Elemental analysis calculated (%) for C15H16N2O3Se · H2O: C: 48.79, H: 4.91, N: 
7.59; found: C: 48.56, H: 4.72, N: 7.66. 
 
4.1.4.8. 3-[(4-Selenocyanatophenyl)carbamoyl]-7-oxabicyclo[2.2.1]hept-5-ene-2-
carboxylic acid (8b) 
From 3,6-epoxy-1,2,3,6-tetrahydrophthalic anhydride obtained by the classic procedure 
described for a Diels-Alder reaction using furan and maleic anhydride as reagents to 
yield the Diels-Alder adduct. Conditions: 24 h at room temperature. The product was 
kept under stirring with water (25 mL) for 4 h, filtered and then washed with ethyl ether 
(2 × 25 mL). A light-yellow powder was obtained. Yield: 20.3%. Mp: 155–156ºC. IR 
(KBr) cm-1: 3267 (NH), 1711 (C=O carboxylic acid), 1689 (C=O, amide). 1H NMR 
(400 MHz, DMSO-d6) δ: 12.19 (s, 1H, COOH), 10.03 (s, 1H, NH), 7.65 (d, 2H, A, J2-
3=J6-5= 9.0 Hz, H2+H6), 7.62 (d, 2H, A, J3-2=J5-6= 9.0 Hz, H3+H5), 6.50 (s, 2H, B, 
H3+H5), 5.14 (s, 1H, B, H5), 5.06 (s, 1H, B, H2), 2.82 (d, 1H, B, J1-6= 9.1 Hz, H1), 2.71 
(d, 1H, B, J6-1= 9.1 Hz, H6). 















170.48 (C=O), 141.07 (A, C4), 137.49+137.08 (B, C4+C5), 135.29 (A, C2+C6), 120.79 
(A, C3+C5), 116.51 (A, C1), 105.93 (CN), 80.82+79.61 (B, C3+C6), 47.96+47.36 (B, 
C1+C2). 
77Se NMR (76 MHz, DMSO-d6) δ: 320.95 (SeCN). MS [m/z (% abundance)]: 
68 (100), 118 (100), 198 (25), 278 (10). Elemental analysis calculated (%) for 
C15H12N2O4Se · ½ H2O: C: 48.35, H: 3.49, N: 7.52; found: C: 48.30, H: 3.70, N: 7.53. 
 
4.2. Biological evaluation 
4.2.1. Cell cultures 
Cell lines were purchased from the American Type Culture Collection (ATCC). PC-3, 
HTB-54, HT-29, MOLT-4, CCRF-CEM, K-562 and MCF-7 cell lines were grown in 
RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine serum (FBS; Gibco), 
100 units/mL penicillin and 100 mg/mL streptomycin (Gibco). BEAS-2B cell line 
(normal epithelial lung) was cultured in DMEM (Gibco), 10% FBS, 100 units/mL 
penicillin and 100 μg/mL streptomycin. 184B5 cells were grown in DMEM/F12 
medium supplemented with 5% FBS, 1× ITS (Lonza), 100 nM hydrocortisone (Aldich), 
2 mM sodium pyruvate (Lonza), 20 ng/mL EGF (Sigma- Aldrich), 0.3 nM trans-
retinoic acid (Sigma-Aldrich), 100 units/mL penicillin and 100 mg/mL streptomycin. 
Cells were maintained at 37ºC and 5% CO2. 
4.2.2. Cytotoxic and antiproliferative activities 
Cell viability was determined using the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide) method at 10 and 100 μM to perform the screening. In order to 
build full dose-response curves five different doses ranging from 0.01 to 100 μM, for 
some compounds lower doses where needed in order to reach 50% cell growth. 
Depending on cell size, 8,000 to 40,000 cells were seeded per well in 96-well plates and 















incubated with 50 μL of MTT (2 mg/mL stock) for 4 h, medium was removed by 
aspiration and formazan crystals dissolved in 150 μL of DMSO. The absorbance was 
measured at 550 nm in a microplate reader (Sunrise reader, Tecan). At least three 
independent experiments performed in quadruplicate were analysed. Results are 
expressed as GI50, the concentration that reduces by 50% the growth of treated cells 
with respect to untreated controls, TGI, the concentration that completely inhibits cell 
growth, and LC50, the concentration that kills 50% of the cells. 
 
4.2.3. Evaluation of cell cycle progression and cell death 
A fixed population of MCF-7 cells per flask were seeded in 25 cm2 flasks then 
incubated overnight. Cultures were treated with the corresponding amount of 
compounds 10a, 8b, DMSO (control) or 6 μM camptothecin (positive control). Seeded 
population was dependent on studied time point: 3 × 106 cells/flask for 24 h or shorter 
treatment, 2 × 106 cells/flasks for 48 h treatment and finally 1 × 106 cells/flask for 72 h 
experiments. Apo-Direct kit (BD Pharmigen) was used to determine cell cycle 
distribution and cell death percentage. Cells were fixed in a 1% paraformaldehyde 
solution in PBS for 30‒40 min at 0ºC, washed with PBS twice and incubated for 30 min 
with 70% ethanol on ice. Staining was performed following manufacturer’s protocol 
and samples were analysed by flow cytometry using a Counter Epics XL cytometer 
(Beckman Counter).  
Inhibition assays cells were pre-treated with 50 μM of the pan-caspase inhibitor Z-
VAD-FMK (BD Pharmigen) or 100 nM of the autophagy inhibitor wortmannin (Santa 
Cruz) for 1 h or 10 μM of chloroquine (Sigma Aldrich). The cells were treated with 80 















following the same methodology stated above. At least three independent experiments 
were performed in duplicate.   
4.2.4. Statistical analysis  
Statistical data represent the mean ± SEM of at least three independent experiments 
performed in duplicate. Mann-Whitney U-test was used to stablish statistical 
significance of differences between control and treatment groups. GraphPad Prism 
version 7 was used, significant differences were considered at p < 0.05.  
  
4.2.5. Protein analysis  
Proteins were detected by western blot. Specific antibodies for LC3B, Beclin-1 
(D40C5), SQSTM1/p62, AMPK, JNK, pAKT (Se473) and the PI3K catalytic subunit 
p110α were obtained from Cell Signalling. Anti-actin (H-300) was from Santa Cruz 
Biotechnology. Anti-rabbit IgG conjugated with peroxidase (Cell Signaling) was used 
as secondary antibody. 
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